These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 31375393)
1. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393 [TBL] [Abstract][Full Text] [Related]
2. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ; Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063 [TBL] [Abstract][Full Text] [Related]
3. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS; Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571 [TBL] [Abstract][Full Text] [Related]
4. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Komrokji R; Ramadan H; Al Ali N; Corrales-Yepez M; Zhang L; Padron E; Lancet J; List A Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S60-3. PubMed ID: 26297280 [TBL] [Abstract][Full Text] [Related]
5. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692 [TBL] [Abstract][Full Text] [Related]
6. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461 [TBL] [Abstract][Full Text] [Related]
7. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368 [TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798 [TBL] [Abstract][Full Text] [Related]
9. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia. Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424 [TBL] [Abstract][Full Text] [Related]
10. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Lee JH; Jang JH; Park J; Park S; Joo YD; Kim YK; Kim HG; Choi CW; Kim SH; Park SK; Park E; Min YH Haematologica; 2011 Oct; 96(10):1441-7. PubMed ID: 21659363 [TBL] [Abstract][Full Text] [Related]
11. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal? Diamantopoulos PT; Viniou NA Leuk Res; 2021 Apr; 103():106543. PubMed ID: 33640709 [TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759 [TBL] [Abstract][Full Text] [Related]
13. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879 [TBL] [Abstract][Full Text] [Related]
14. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405 [TBL] [Abstract][Full Text] [Related]
15. Platelet Doubling After First Decitabine Cycle Predicts Response and Survival of Myelodysplastic Syndrome Patients. Lu PF; Deng LN; Meng FK; Wang Y; Xiao M; Li DJ Curr Med Sci; 2022 Feb; 42(1):77-84. PubMed ID: 35089492 [TBL] [Abstract][Full Text] [Related]
16. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415 [TBL] [Abstract][Full Text] [Related]
17. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386 [TBL] [Abstract][Full Text] [Related]
18. Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome: Japanese retrospective multicenter study. Ito Y; Ohyashiki K; Hirai H; Ogawa S; Mitani K; Hotta T; Bessho M; Naoe T; Mizoguchi H; Uchiyama T; Omine M Int J Hematol; 2005 Oct; 82(3):236-42. PubMed ID: 16207597 [TBL] [Abstract][Full Text] [Related]
19. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. Steensma DP; Baer MR; Slack JL; Buckstein R; Godley LA; Garcia-Manero G; Albitar M; Larsen JS; Arora S; Cullen MT; Kantarjian H J Clin Oncol; 2009 Aug; 27(23):3842-8. PubMed ID: 19528372 [TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes. Tong H; Hu C; Zhuang Z; Wang L; Jin J Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]